BSE SELECT IPO PB	8.4
BSE SELECT IPO PE	56.1
BSE SELECT IPO DIV	0.2
BSE SELECT IPO EPS	80.5

Bse Select Ipo News, Corporate filings and Earnings/Conference Calls

Pharmaceuticals company Anthem Biosciences announced Q2FY27 results Standalone Financial Highlights: Revenue from operations: For Q2FY27, standalone revenue from operations stood at Rs 5,721.08 million, growing by 49.05% QoQ from Rs 3,838.42 million in Q1FY27 and increasing by 3.51% YoY against Rs 5,527.03 million in Q2FY26. For H1FY27, revenue reached Rs 9,559.50 million, registering a decline of 12.41% YoY from Rs 10,913.71 million recorded in H1FY26. Total income: Standalone total income for Q2FY27 reached Rs 6,368.03 million, marking an increase of 54.40% QoQ compared to Rs 4,124.42 million in Q1FY27 and up 5.08% YoY from Rs 6,060.25 million in Q2FY26. For H1FY27, total income stood at Rs 10,492.45 million, displaying a YoY reduction of 10.46% against Rs 11,717.64 million in H1FY26. Profit before tax (PBT): For Q2FY27, PBT was reported at Rs 3,041.17 million, demonstrating a robust QoQ increase of 123.03% from Rs 1,363.60 million in Q1FY27 and a YoY expansion of 20.06% from Rs 2,533.02 million in Q2FY26. For H1FY27, PBT touched Rs 4,404.77 million, which corresponds to a mild decrease of 2.60% YoY against Rs 4,522.40 million in H1FY26. Profit after tax (PAT): Standalone PAT for Q2FY27 came in at Rs 2,208.86 million, up significantly by 116.54% QoQ over Rs 1,020.09 million in Q1FY27 and growing by 11.31% YoY compared to Rs 1,984.34 million in Q2FY26. For H1FY27, PAT accumulated to Rs 3,228.95 million, down by 6.89% YoY from Rs 3,467.73 million in H1FY26. Earnings per share (EPS): Basic EPS for Q2FY27 stood at Rs 3.92, increasing by 116.57% QoQ from Rs 1.81 in Q1FY27 and rising by 10.73% YoY from Rs 3.54 in Q2FY26. For H1FY27, basic EPS was Rs 5.74, revealing a YoY downshift of 7.27% compared to Rs 6.19 in H1FY26. Consolidated Financial Highlights: Revenue from operations: Consolidated revenue from operations for Q2FY27 was recorded at Rs 5,940.32 million, rising by 42.04% QoQ from Rs 4,182.18 million in Q1FY27 and showing a YoY growth of 7.91% compared to Rs 5,505.04 million in Q2FY26. For H1FY27, consolidated operational revenue accumulated to Rs 10,122.50 million, which is a YoY drop of 7.25% against Rs 10,913.71 million in H1FY26. Total income: For Q2FY27, consolidated total income reached Rs 6,529.29 million, advancing by 47.35% QoQ from Rs 4,431.07 million in Q1FY27 and scaling up by 9.14% YoY over Rs 5,982.56 million in Q2FY26. For H1FY27, total income reached Rs 10,960.36 million, expressing a 5.62% YoY drop from Rs 11,612.77 million in H1FY26. Profit before tax (PBT): Consolidated PBT for Q2FY27 was recorded at Rs 2,963.73 million, achieving a sequential step-up of 104.99% QoQ against Rs 1,445.81 million in Q1FY27 and growing YoY by 29.08% from Rs 2,296.03 million in Q2FY26. For H1FY27, consolidated PBT climbed to Rs 4,409.54 million, showing a YoY growth of 6.04% over Rs 4,158.51 million in H1FY26. Profit after tax (PAT): In Q2FY27, consolidated PAT stood at Rs 2,114.63 million, marking a sequential rise of 76.31% QoQ from Rs 1,199.41 million in Q1FY27 and expanding YoY by 21.93% over Rs 1,734.28 million in Q2FY26. For H1FY27, consolidated PAT hit Rs 3,314.04 million, accelerating YoY by 7.17% over Rs 3,092.18 million in H1FY26. Earnings per share (EPS): Basic consolidated EPS for Q2FY27 was Rs 3.75, representing a QoQ expansion of 76.06% from Rs 2.13 in Q1FY27 and a YoY expansion of 21.36% relative to Rs 3.09 in Q2FY26. For H1FY27, basic EPS was Rs 5.89, showcasing a 6.70% YoY acceleration over Rs 5.52 in H1FY26. Segment-wise Performance: Contract Research, Development and Manufacturing Organization (CRDMO): This segment pulled in revenue of Rs 5,092.69 million during Q2FY27, recording an expansion of 49.43% QoQ from Rs 3,408.02 million in Q1FY27 and expanding by 9.23% YoY over Rs 4,662.27 million in Q2FY26. For H1FY27, the segment generated revenue of Rs 8,500.71 million, which is a decline of 7.55% YoY compared to Rs 9,195.36 million in H1FY26. Speciality Ingredients: This business segment achieved a revenue of Rs 847.63 million in Q2FY27, representing a QoQ growth of 9.49% from Rs 774.16 million in Q1FY27 and a modest YoY rise of 0.58% against Rs 842.77 million in Q2FY26. For H1FY27, it secured revenue of Rs 1,621.79 million, pointing to a YoY reduction of 5.62% compared to Rs 1,718.35 million in H1FY26. Ajay Bhardwaj, Chairman, Managing Director and CEO, Anthem Biosciences, said: “We are pleased to report a robust performance for Q2FY27, driven by our CRDMO revenue stream. Underlying demand continues to remain strong and we are confident in our ability to sustain growth and create long-term value for all stakeholders. We expanded our EBITDA and PAT margins year-on-year. By maintaining strict discipline around cost efficiencies, yield optimization, and workforce productivity, we have further solidified our industry-leading margins, and are well-positioned to sustain this performance all year”. Result PDF

Bse Select Ipo News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Bse Select Ipo from all sources in a single place.